About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, September 8th, 2017

The QualityStocks
Daily Stock List


Imaging3, Inc. (IGNG)

MarketWatch, Investors Hub, and OTC Markets reported on Imaging3, Inc. (IGNG), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Imaging3, Inc. is a provider of advanced technology medical imaging devices. The Company has developed a patented medical imaging technology named SmartScan™. This technology will produce 3D medical diagnostic images in real time in each of single 3D Safe-Scan, Continuous 3D Scan, and CT Safe-Scan mode. Imaging3 is headquartered in Burbank, California.

Imaging3’s technology will enable healthcare professionals utilizing Imaging3 lightweight portable devices to view 3D, high resolution images of almost any part of the human body in real time, even as they are performing procedures. 

Burbank is the Company’s center for operations. In addition, it is the center for the development of Imaging3’s proprietary and patented 3D medical imaging system, the Dominion Volumetric Imaging Scanner (DVIS). This technology uses high resolution fluoroscopy to build 3D images in real time. Furthermore, the Company’s technology exposes patients to considerably less harmful radiation than contemporary imaging technologies.   

The Dominion Volumetric Imaging Scanner (DVIS) is a proprietary and patented innovative mobile fluoroscopy technology. It produces high quality 3D images in Continuous 3D Scan mode, Single 3D SafeScan mode, and high quality 2D images in Continuous 2D Scan mode. DVIS is the only product in existence that can produce a combination of 2D, 3D, and CT imagery in a single device. 

Imaging3’s products also include 3D Printers, C-Arms. Mini C-Arms, and Rentals. The Company offers new, used, and demo C-Arms in all price ranges. It also offers its C-Arm rental programs. 

Imaging3 signed a DVIS Software Remediation Proposal on August 26, 2016, with CriTech Research, Inc. of Saline, Michigan. CriTech agreed to document, verify, and validate Imaging3’s patented device software for presentation to the Food and Drug Administration (FDA) as part of Imaging3’s planned submission of an application for a 510(k) approval for its Volumetric Imaging Scanner (VIS). 
CriTech Research completed its remediation review and testing of Imaging3 DominionVI SmartScan™ software. 

Imaging3 plans to complete and submit a 510K application to the FDA for its unique 3D scanning device. On June 5, 2017, it hired Med-Device Consulting, Inc. to facilitate the 510(k) application to the FDA to obtain approval for its Dominion VI imaging device with patented SmartScan™ 3D technology.

Moreover, on June 14, 2017, Imaging3 hired Intertek, Inc. to remediate the hazard analytics and manage the FDA guidance protocols of submission requirements outlined by the FDA, to obtain approval for Imaging3’s Dominion VI imaging device.

Mr. Dane Medley, Imaging3 President, said: “We continue to have extraordinarily high standards in our selection of vendors. The engagement of Intertek is yet another example, along with Med-Device Consulting, who is assisting with our 510K applications generally, and CriTech Research, who is assisting with the immense software component of our Dominion VI imaging device. This game-plan of working only with the best maximizes our chances of a successful outcome with the FDA.”

Imaging3, Inc. (IGNG), closed Friday's trading session at $0.012, even for the day, on 72,060 volume with 7 trades. The average volume for the last 60 days is 383,011 and the stock's 52-week low/high is $0.008/$0.072.

Wearable Health Solutions, Inc. (WHSI)

MarketWatch, TradingView, and InvestorsHub reported on Wearable Health Solutions, Inc. (WHSI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Wearable Health Solutions, Inc. is a personal medical alarm and wearable device manufacturer. It provides mobile health (mHealth) products and services to dealers and distributors internationally. On June 9, 2016, Medical Alarm Concepts Holding, Inc. announced that it changed its name and became Wearable Health Solutions, Inc.  A solutions-based enterprise, Wearable Health Solutions is headquartered in King of Prussia, Pennsylvania. 

The Company chiefly focuses on connected, mobile, and wearable IoT (Internet of Things) devices. Additionally, it concentrates on supporting services that provide scalable and evolving real-time personal protection, health information, and data-informed decision-making, to consumers and organizations within the healthcare sector.

Wearable Health Solutions provides unique wearable healthcare products, tracking (GPS, Bluetooth) services, and turn-key solutions. These allow users to be hands-on with their health. 

The Company has its iHelp+ 3G product. The iHelp+ provides the latest in 3G wireless coverage using AT&T services. The product is compact and lightweight at less than 1.5oz. Loud, clear audio, and voice prompts enable the user to know the status of their pendant at all times. 

The iHelp+ has a fall detection system; it may be turned on or off by the dealer only. Furthermore, the iHelp+ 3G™ includes additional safety options. This includes Real GPS, a Find Me tracking Function, and Geo-Fencing. The iHelp+ is easily programmed using the Company’s iHelp™ Cloud web portal. 

Wearable Health Solutions is now shipping the iHelp+ 3G™ mobile medical alert system to dealers in the United States and Canada. The iHelp+ 3G™ and the iHelp Cloud dealer portal are now integrated with 10 central stations.

Wearable Health Solutions has its iHelp Dealer Program. Exclusive features of this program for dealers include special equipment pricing; a universal iHelp+ 3G™ interface, and an iHelp cloud web portal. Features also include technical guidance; marketing support and promotional kit, as well as a strong brand presence and corporate identity.

The Company has the above-mentioned iHelp Cloud. This is its full-service, proprietary, web-based, account management portal. It provides all the necessary tools to help dealers manage their iHelp+ 3G™ user accounts. The design of it is to be a simple instrument for dealers to maintain direct control of their customers’ devices, cellular network, as well as monitoring functions.

Wearable Health Solutions, Inc. (WHSI), closed Friday's trading session at $0.0257, even for the day. The average volume for the last 60 days is 17,097 and the stock's 52-week low/high is $0.015/$0.169.

Greenkraft, Inc. (GKIT)

Penny Stock Newsletter, PREPUMP STOCKS, DSR News, HEROSTOCKS, PHUB News, Damn Good Penny Picks, Penny Picks, DamnGoodPennyStock, Stock Brain, and Penny Stock Hub reported on Greenkraft, Inc. (GKIT), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Greenkraft, Inc. manufactures and markets alternative commercial forward trucks for different vehicle classes in the United States. In addition, the Company provides engines, and offers alternative fuel systems to convert petroleum based vehicles to run on natural gas and propane fuels. Greenkraft is a nationally recognized player in the alternative fuel engine and vehicle market. Formed in 2008, the Company is based in Santa Ana, California.

Greenkraft has reached near zero emissions on different alternative fuel products running on alternative fuels. These near zero emission engines and trucks can be used in the transportation industry across the United States. The near zero emission engine Greenkraft is working on is an 8.0 liter. It will be used in the Company’s Class 6 and Class 7 trucks running on CNG and LPG. 

Greenkraft established to introduce clean, green, efficient, automotive products that run on alternative fuels. Its commercial trucks are powered by alternative fuels, including CNG and LPG in Classes 3, 4, 5, 6, and 7. 

Greenkraft designs, develops, and manufactures compressed American natural gas and propane gas forward cabin trucks, alternative fuel systems, and alternative fuel engines. The Company’s products are all environmentally friendly solutions. Greenkraft offers a 6.0 Liter CNG, a 6.0 Liter Propane, an 8.8 Liter CNG, and also an 8.8 Liter Propane engine.   
Greenkraft is currently manufacturing trucks designed to run with a package from Allison Transmission Holdings, Inc. (Indianapolis, Indiana). The Allison package will provide a wholly automatic transmission for Greenkraft's customers. Allison Transmission is the world's largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles.  

Greenkraft plans to introduce an entire new line of trucks called the G3 and G4. These are larger-sized trucks in weights of 26,000 lbs. and 33,000 lbs. respectively.

Recently, Greenkraft announced that it is experiencing a significant increase in demand for its trucks from various fleet operators all across the nation.  This increase in demand is because of the multitude of government incentives available to companies that switch to alternative energy trucks.

Greenkraft is starting to profit very heavily from this demand increase because it is getting orders from truck fleet operators ranging from 10 to 100 trucks, many of which have their own filling stations where they are getting CNG for low prices. This in due course translates into millions of dollars of revenue for Greenkraft, much of which comes directly from these diverse government incentives.

Greenkraft, Inc. (GKIT), closed Friday's trading session at $0.09251, down 15.82%, on 9,375 volume with 4 trades. The average volume for the last 60 days is 11,462 and the stock's 52-week low/high is $0.019/$0.20.

EOS, Inc. (EOSS)

MarketWatch, OTC Markets, and Trading View reported on EOS, Inc. (EOSS), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

EOS, Inc. has a wide-ranging distribution network of associates with numerous dealer companies providing health care, beauty care, as well as environment friendly cleaning products in Asia. Since Q1 of 2017, the Company has expanded its marketing channels in China and Southeast Asian countries. EOS has its headquarters in Taipei, Taiwan. Established in 2015, the Company lists on the OTC Markets Group’s OTCQB.

EOS’ products include moisturizers, serums, cleansers, toners, exfoliators, acne and oil correctors, facial masks, cleansing devices, and sun care products. The Company concentrates on the marketing and distribution of skin care products to resellers in Taiwan. EOS involves in the distribution and marketing of skin care products manufactured by A.C. (USA), Inc.

On April 22, 2017, Mr. Ben Yang, the chief representative of Asian market, EOS, Inc., signed agency contracts in Nanning City, Guangxi, China, with three owners of new flagship stores being launched there. There are four flagship stores set up in China, including the first one in Quanzhou. This will help contribute to broadening the business of EOS in China. Nanning City is the largest economy of Guangxi province.

On April 25, 2017, the EOS Singapore flagship store celebrated its grand opening. After the flagship stores opened in Singapore, the associate EOS sales teams in Malaysia, Indonesia, Thailand, and Cambodia are also making aggressive moves.

EOS announced in May of this year that its sales force launched an important base in Taiwan to promote business in the markets of China and Asia. Effective on May 3, 2017, EOS acquired all the issued and outstanding shares of Emperor Star International Trade Co. Ltd. This is the trading team that plays an important part in the supply chain of EOS products.

EOS acquired Emperor Star trading company in Taipei, Taiwan to strengthen its business and prepare for the challenge of OBOR (One Belt and One Road) development in Malaysia, Indonesia, Thailand, and Cambodia.

Emperor Star incorporated in Taiwan in November of 2015. It has been distributing highly innovative health and beauty care products and environmentally friendly cleaning products, with premier growth in China and Asia.

EOS, Inc. (EOSS), closed Friday's trading session at $2.30, down 3.36%, on 2,943 volume with 9 trades. The average volume for the last 60 days is 387 and the stock's 52-week low/high is $0.10/$4.50.

Inspyr Therapeutics, Inc. (NSPX)

Zacks and BUYINS.NET reported on Inspyr Therapeutics, Inc. (NSPX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Inspyr Therapeutics, Inc. is a clinical-stage biotechnology company listed on the OTC Markets. It is developing novel prodrug therapeutics for the treatment of cancer. Mipsagargin is its lead agent. It is in human clinical trials for patients with many different tumor types. Inspyr Therapeutics’ team has considerable pharmaceutical industry and scientific experience. The Company has its corporate office in Westlake Village, California. 

Inspyr Therapeutics is developing a novel technology platform. It combines a powerful therapeutic (thapsigargin) with a patented prodrug delivery system, which targets the release of drugs within solid tumors without the side effects of chemotherapeutic agents. This unique platform technology has the potential to work across a spectrum of drugs that precisely target different cancers.   

Mipsagargin (G-202) is a prodrug in human clinical trials for patients with hepatocellular carcinoma (HCC, or liver cancer), glioblastoma (GBM, or brain cancer) and prostate cancer. Mipsagargin has been studied in a Phase 2 clinical trial in patients with hepatocellular carcinoma (liver cancer). It has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication. 

Mipsagargin is presently undergoing evaluation in an open-label, single-arm, Phase II clinical study in patients with glioblastoma (brain cancer). In addition, it is undergoing evaluation in two Phase II clinical pilot studies in patients with prostate and clear cell renal cancer. 

Inspyr Therapeutics has begun the second development program for Mipsagargin as part of a combination therapeutic approach. This new program centers on the treatment of gastric cancer. The Company has started a preclinical study in gastric cancer PDX tumor models that express varying levels of PSMA, the target of Mipsagargin. In this initial study, Mipsagargin will undergo evaluation initially in combination with paclitaxel.  

Inspyr Therapeutics also plans to evaluate Mipsagargin in combination with DC101 (Cyramza® surrogate antibody). Paclitaxel and Cyramza® are approved for the treatment of gastric cancer. Inspyr expects to share initial results from this initial study in the second half of 2017.  
Inspyr Therapeutics and Lewis and Clark Pharmaceuticals announced in late May of this year that they entered into an agreement to create an integrated company with a proprietary platform driving a pipeline of novel therapeutics. With the agreement, Inspyr Therapeutics will purchase Lewis and Clark in an all-stock transaction.

Lewis and Clark Pharmaceuticals is a privately-held biotechnology enterprise. It is developing novel proprietary compounds from an industry-leading technology platform founded on adenosine chemistry and biology. Lewis and Clark also maintains fully-equipped, state-of-the-art organic and analytical chemistry laboratories in Charlottesville, Virginia.

Inspyr Therapeutics, Inc. (NSPX), closed Friday's trading session at $0.33, even for the day, on 10 volume with 1 trade. The average volume for the last 60 days is 1,938 and the stock's 52-week low/high is $0.20/$4.99.


The QualityStocks
Company Corner



The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $0.712, up 2.20%, on 181,964 volume with 155 trades. The stock’s average daily volume over the past 60 days is 89,748 and its 52-week low/high is $0.6171/$0.90.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABcann Global Appoints Barry Fishman as Chief Executive Officer

ABcann Releases High Level CBD Product and Launches Initial Oils Strategy

NetworkNewsWire Announces Publication Discussing Canadian Cannabis Investment Options

Patriot One Technologies, Inc. (TSX.V:PAT) (OTCQB:PTOTF)

The QualityStocks Daily Newsletter would like to spotlight Patriot One Technologies, Inc. (PTOTF). Today, Patriot One Technologies, Inc. closed trading at $0.6296, up 0.96%, on 104,826 volume with 64 trades. The stock’s average daily volume over the past 60 days is 50,204, and its 52-week low/high is $0.4665/$1.49.

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) is leveraging seven years of development to create powerful technologies that mitigate security risks by detecting concealed weapons via novel radar technology.

Developed through a NATO-funded project at McMaster University, Patriot One's disruptive NForce CMR1000 technology is the first cost-effective solution available for active shooter prevention, the need for which is evidenced by an increasing number of active shooter events in the United States and worldwide.

A recent study that surveyed data going back as far as 1966 demonstrates that there have been significantly more mass shootings in the U.S. than any other country for decades. Statistics for the 46-year period shows that even though America only holds 5% of the world's population, it took count of 31% of all public mass shootings. According to the FBI, there were an astounding 160 incidents from 2000 to 2013 that resulted in 486 people killed and 557 wounded. In years 2014 and 2015, there were nearly six times as many incidents compared to 2000 and 2001. The disturbing trend shows that there will be increasingly more incidents if better preventative measures aren't taken.

Patriot One's patent-pending solution to this alarming progression enables stand-off detection, even on moving targets, with a "cognitive" ability to learn and identify new threats once deployed. The product is not intended to threaten the constitutional rights of legal gun carriers, and it is also void of privacy and health concerns of traditional detection technologies, which require subject compliance, present false positives, and are often slow, inefficient and costly.

In contrast, Patriot One's technology is small in size and can be "covertly" placed in a doorway or hallway to prevent planned attacks in public places like schools, concerts, stadiums, banks, airports, offices, hospitals, shopping centers and other facilities for which there are concerns. With this method of deployment, there is no subject compliance requirement. In addition, because an image of the target is not generated, there are also no privacy concerns. Detection is real-time and entirely computer-based, which means there is no need for human operators to alert security. This eliminates the safety concerns of a would-be operator, reduces the expense of a human operator, and enables overall accuracy of 93%.

The technology is designed to identify if someone is carrying a gun, knife, suicide vest, etc., by analyzing metal content and relating it to a database of known weapon signatures. Patriot One believes the widespread use of this detection technology could act as an effective deterrent, thereby diminishing the epidemic phenomena of active shooters across the nation and around the world.

The company is guided by a team of experts in the areas of high-frequency electromagnetics, counter-terrorism, conflict resolution, government/corporate interface, sensor development, proactive security and business development. Senior Management has partnered with, among other affiliates, Ridge Global, which was founded by recently appointed advisory board member Tom Ridge, the first head of the Department of Homeland Security, first U.S. Secretary of Homeland Security, and 43rd governor of Pennsylvania.

Along with its partners, Patriot One is addressing global concerns of active shooting events and other violent terrorist attacks. The key is to short-circuit the event through effective prevention technologies and security protocols. Disclaimer

Patriot One Technologies, Inc. Company Blog

Patriot One Technologies, Inc. News:

Patriot One Completes FCC and IC Submission in Preparation for PATSCAN CMR Commercialization

NetworkNewsWire Releases Exclusive Audio Interview with Patriot One Technologies, Inc. (PTOTF)

Patriot One Initiates Pacific Rim Sales with Aotea Security of New Zealand

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.2665, up 1.97%, on 264,912 volume with 134 trades. The stock’s average daily volume over the past 60 days is 258,210, and its 52-week low/high is $0.065/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

Biosynthesis Could Reduce Regulatory Hurdles for Cannabis Researchers -- CFN Media

InMed Announces Appointment of Creative Capital Media

InMed Announces Publication in European Journal of Pain

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.0585, off by 1.52%, on 6,066,545 volume with 272 trades. The stock’s average daily volume over the past 60 days is 4,247,081, and its 52-week low/high is $0.002/$0.0995.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

PCAOB Registered CPA Firm Engaged to Initiate Audit on PotNetwork Holding, Inc.’s Recent Revenues

Mayweather vs. McGregor Event Brings Unprecedented Exposure to Diamond CBD and PotNetwork Holdings, “POTN”, as Sponsored Contenders Take the Spotlight

With Revenues over $1,459,137, PotNetwork Holding, Inc.’s Diamond CBD Continues to Exceed Projections, Bringing in the Highest Level of Monthly Sales to Date

ProBility Media Corp. (PBYA)

The QualityStocks Daily Newsletter would like to spotlight ProBility Media Corp. (PBYA). Today, ProBility Media Corp. closed trading at $0.537, even with yesterday's close. The stock’s average daily volume over the past 60 days is 2,383, and its 52-week low/high is $0.1205/$1.16.

ProBility Media Corp. (PBYA) based in Houston, TX, is an EdTech Company that is building the first full service training and career advancement brand for the skilled trades. Through both acquisitions and organic growth, ProBility is executing a disruptive strategy of defragmenting the market place of disparate companies servicing fifteen vertical categories in over sixty skilled trades. ProBility has positioned itself as a key industrial training resource for individuals, small- and medium-size businesses as well as enterprise customers offering consistent high-quality training services and materials for education, testing, and career advancement.

Through its Electrical Training Division, the company has become the biggest wholesaler of electrical codes and test preparation materials in the U.S., while its Construction Training Division is one of the largest certification providers in the country, with programs in 22 states, and continuing to grow. The company serves corporate accounts and government buyers, and also offers advisory services for companies of all sizes.

Companies currently under the ProBility Media conglomerate include:

  • Brown Technical Media Corp. – An online web business with multiple micro web sites featuring training materials and codes and standards sought by engineers, construction workers, scientists and other tradesmen in a wide variety of fields.
  • Brown Technical Publications – A proprietary publishing business generating copyrighted training materials for engineers, construction workers, scientists and other tradesman in a wide variety of fields.
  • 1ExamPrep – E-Learning, education and exam preparation for contractors via the cheapest, fastest and most effective exam prep school in the industry instituting our 4-point proven learning system.
  • National Electrical Wholesale Providers – In the business of distributing wholesale industrial, commercial and residential training materials including HVAC, plumbing and electrical.

ProBility's technology platform features virtual reality training for the crane business to be expanded into other industries, online subscription services for enterprise level companies, and recurring revenue streams. In addition, the company is already beginning to explore international expansion options, supported by the fact that other countries have adopted U.S. based codes, and have used U.S. training services.

The company's acquisition strategy targets operations that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, QC firms, and additional vocational industries. Disclaimer

ProBility Media Corp. Company Blog

ProBility Media Corp. News:

ProBility to Donate a Portion of ASME Profits to Hurricane Harvey Flood Victims

NetworkNewsWire Announces Publication on the Value of EdTech Leaders to the Skilled Labor Workforce

ProBility Completes Acquisition of Cranbury International


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Stock Commander
(AHROQ) +531.91%


Trader Power News
(ONS) +124.44%


(KURA) +72.26%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251